Boston Financial & Equity Corporation recently closed a $1 million lease line for an emerging growth company based in Cambridge, Massachusetts. The company is an integrated drug discovery and development company focused on the immune system. The company has attracted over $50 million in series A funding to build a fully integrated biopharmaceutical company from the ground up. Although the company has $20 million in cash, they burn $2 million a month. When they have FDA clearance, they expect another round of funding. Their first takedown is for a hardware/software enterprise platform for R&D, and moving forward for needed lab equipment to equip their new lab space.